Ausgabe 3/2020
Inhalt (36 Artikel)
Sexual health after a breast cancer diagnosis in young women: clinical implications for patients and providers
Sydney Marsh, Virginia F. Borges, Helen L. Coons, Anosheh Afghahi
Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients
Daqin Mao, Hilal Hachem, Hong Chang, Danai Dima, Joshua Dower, Michael Wismer, John K. Erban, Karen M. Freund, Susan K. Parsons
Clinical practice to address tamoxifen nonadherence
Richard R. Love, Michael Baum, Susan M. Love, Andrea M. Straus
Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score
Puneet Singh, Sarah E. Tevis, Carolyn S. Hall, Salyna Meas, Rosa F. Hwang, Anthony Lucci
Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer
Yi Zhang, Jianfang Liu, Praveen-Kumar Raj-Kumar, Lori A. Sturtz, Anupama Praveen-Kumar, Howard H. Yang, Maxwell P. Lee, J. Leigh Fantacone-Campbell, Jeffrey A. Hooke, Albert J. Kovatich, Craig D. Shriver, Hai Hu
UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin
Yanfang Yang, Jing Zhao, Yiran Mao, Gu Lin, Fangxuan Li, Zhansheng Jiang
Bone-protective and anti-tumor effect of baicalin in osteotropic breast cancer via induction of apoptosis
Bangmin Wang, Tao Huang, Qigen Fang, Xu Zhang, Junhui Yuan, Mengjie Li, Hong Ge
Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study
Anna Bozzini, Luca Nicosia, Giancarlo Pruneri, Patrick Maisonneuve, Lorenza Meneghetti, Giuseppe Renne, Andrea Vingiani, Enrico Cassano, Mauro Giuseppe Mastropasqua
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
S. F. Dent, J. Botros, M. Rushton, O. Aseyev, M. N. Levine, W. R. Parulekar, P. O’Brien, M. Burnell, K. I. Pritchard, B. E. Chen, L. E. Shepherd
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes?
Valerie Lai, Omar Hajjaj, Dan Le, Aria Shokoohi, Stephen Chia, Christine Simmons
Screening women at high risk for breast cancer: one program fits all?
Naama Hermann, Adi Klil-Drori, Fernando A. Angarita, Shelley Westergard, Vivianne Freitas, Anabel Scaranelo, David R. McCready, Tulin D. Cil
Diffuse tensor imaging of lower extremities: a novel MR imaging technique for chemotherapy-induced peripheral neuropathy
Pavani Chalasani, Mihra Taljanovic, Jenn Segar, Kiah Farr, Hninyee Win, Betsy C. Wertheim, Michele Chu-Pilli, Sima Ehsani, Denise J. Roe, Lana Gimber
Language impairment among patients with different types of cancer. Comparison with healthy adults
Kalliopi Megari
Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
E. Montagna, E. Pagan, V. Bagnardi, M. Colleoni, G. Cancello, E. Munzone, S. Dellapasqua, N. Bianco, G. Campennì, M. Iorfida, M. Mazza, A. De Maio, P. Veronesi, C. Sangalli, B. Scateni, G. Pettini, G. Pravettoni, K. Mazzocco, V. Galimberti
Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy
Chihwan Cha, Janghee Lee, Dooreh Kim, Soeun Park, Soong June Bae, Na Lae Eun, Sung Gwe Ahn, Eun Ju Son, Joon Jeong
Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer
Max O. Meneveau, Jessica Keim-Malpass, T. Fabian Camacho, Roger T. Anderson, Shayna L. Showalter
Utility of 70-kV single-energy CT in depicting the extent of breast cancer for preoperative planning
Marehiko Hisoshima, Misugi Urano, Kazuya Ohashi, Masaki Ogawa, Shingo Omata, Shiro Yoshida, Tatsuya Toyama, Yuta Shibamoto
Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study
Jens Sundbøll, Dóra Körmendiné Farkas, Kasper Adelborg, Lidia Schapira, Suzanne Tamang, Mette Nørgaard, Mark R. Cullen, Deirdre Cronin-Fenton, Henrik Toft Sørensen
The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients
Dharmendra Singh, Avik Mandal
Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer
Naomi Y. Ko, Muhammad M. Qureshi, Oluwadamilola T. Oladeru, Michael R. Cassidy, Lauren Oshry, Minh-Tam Truong, Ariel E. Hirsch
A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection
Sarah Nietz, Daniel S O’Neil, Oluwatosin Ayeni, Wenlong Carl Chen, Maureen Joffe, Judith S Jacobson, Alfred I Neugut, Paul Ruff, Witness Mapanga, Ines Buccimazza, Urishka Singh, Sharon Čačala, Laura Stopforth, Boitumelo Phakathi, Tobias Chirwa, Herbert Cubasch
Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia
Kate R. Pawloski, Nicole Christian, Andrea Knezevic, Hannah Y. Wen, Kimberly J. Van Zee, Monica Morrow, Audree B. Tadros
Lobular neoplasia occult on conventional imaging and diagnosed on MRI-guided biopsy: can we estimate upgrade on surgical pathology?
Yoav Amitai, Tehillah S. Menes, Anabel Scaranelo, Rachel Fleming, Supriya Kulkarni, Sandeep Ghai, Tulin Cil, Susan Done, Vivianne Freitas
Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark
Elsebeth Lynge, Anna-Belle Beau, My von Euler-Chelpin, George Napolitano, Sisse Njor, Anne Helene Olsen, Walter Schwartz, Ilse Vejborg
Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors
Cathleen Y. Xing, Michelle Doose, Bo Qin, Yong Lin, Tiffany L. Carson, Jesse J. Plascak, Kitaw Demissie, Chi-Chen Hong, Elisa V. Bandera, Adana A. M. Llanos
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer
Yunan Han, Zhi-Feng Miao, Min Lian, Lindsay L. Peterson, Graham A. Colditz, Ying Liu
Prognostic associations of plasma hepcidin in women with early breast cancer
Katarzyna J. Jerzak, Ana E. Lohmann, Marguerite Ennis, Elizabeta Nemeth, Tomas Ganz, Pamela J. Goodwin
Factors associated with being diagnosed with high severity of breast cancer: a population-based study in Queensland, Australia
Kou Kou, Jessica Cameron, Joanne F. Aitken, Philippa Youl, Gavin Turrell, Suzanne Chambers, Jeff Dunn, Chris Pyke, Peter D. Baade
The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study
T. J. A. van Nijnatten, L. P. T. van Tiel, A. C. Voogd, C. G. M. Groothuis-Oudshoorn, S. Siesling, M. B. I. Lobbes
Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer
Kimberley T. Lee, Lisa Jacobs, Elaine M. Walsh, Vered Stearns, Jodi B. Segal
Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction
A. Frisell, J. Lagergren, M. Halle, J. de Boniface
Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes
Frederik Deman, Kevin Punie, Annouschka Laenen, Patrick Neven, Eva Oldenburger, Ann Smeets, Ines Nevelsteen, Chantal Van Ongeval, Adinda Baten, Timothy Faes, Melissa Christiaens, Hilde Janssen, Caroline Weltens, Christine Desmedt, Hans Wildiers, Giuseppe Floris
Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients
Kadri Altundag